(Q36677411)

15 August 2017

1 reference

title

Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast (English)

1 reference

15 August 2017

1 reference

Claus Kroegel

1

1 reference

15 August 2017

Martin Foerster

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

16

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

109-124

1 reference

Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Phosphodiesterase 4 inhibitors for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Syntheses and Biological Activities of 3-(Cyclopentyloxy)-4-methoxybenzamides and Analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Structural and inflammatory changes in COPD: a comparison with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Some examples of regression towards the mean

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Regression towards the mean

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

Contemporary management of chronic obstructive pulmonary disease: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.109

10.1517/13543784.16.1.109

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference